Transcenta Licenses HiCB Bioprocessing Tech to WuXi Biologics
Suzhou – September 13, 2026 -- Transcenta Therapeutics has licensed its Highly Intensified Continuous Bioprocessing (HiCB) platform to WuXi Biologics under a non-exclusive technology agreement, securing an upfront payment of RMB 10 million plus future milestone payments.
Transcenta and subsidiary HJB grant WuXi Biologics non-exclusive rights to HiCB and ExcelPro media
Under the deal, Transcenta and its subsidiary HJB will license certain technologies tied to the HiCB continuous bioprocessing platform and its ExcelPro cell culture media to WuXi Biologics and its affiliates. WuXi Biologics will become a strategic CMC development partner supporting molecules across Transcenta's pipeline.